Using moxibustion to prevent hemorrhagic cystitis after stem cell transplantation
Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation
NA · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06198517
This study is testing if moxibustion can help prevent bladder problems in patients getting stem cell transplants.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 266 (estimated) |
| Ages | 14 Years to 60 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (other) |
| Locations | 4 sites (Zhengzhou, Henan and 3 other locations) |
| Trial ID | NCT06198517 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of moxibustion as a preventive treatment for hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 266 hematological patients will be randomly assigned to either a control group receiving conventional treatment or an experimental group receiving moxibustion therapy starting from the first day after transplantation. Urine tests will be conducted at various intervals to monitor the presence of viruses and assess symptoms related to hemorrhagic cystitis. The study aims to evaluate the impact of moxibustion on the incidence and severity of this complication.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 14-60 with pernicious blood diseases or severe aplastic anemia undergoing allo-HSCT.
Not a fit: Patients who have skin sensitivities at the moxibustion site or those who have undergone specific pre-treatment protocols may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of hemorrhagic cystitis in patients undergoing allo-HSCT.
How similar studies have performed: While moxibustion is a traditional therapy, its application in preventing hemorrhagic cystitis after allo-HSCT is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF); 2. Age: 14-60 years; 3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT; Exclusion Criteria: 1. refuse to participate in this clinical study; 2. The corresponding skin at the moxibustion site is broken or sensitive; 3. allo-HSCT pretreated with the RIC program;
Where this trial is running
Zhengzhou, Henan and 3 other locations
- Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou — Zhengzhou, Henan, China (RECRUITING)
- Yi Zhang — Wuhan, Hubei, China (RECRUITING)
- Hematology Department, The First People's Hospital of Yunnan — Kunming, Yunnan, China (RECRUITING)
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou — Hangzhou, Zhejiang, China (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Yi Zhang, Dr
- Email: zy188603@163.com
- Phone: +86 15639790587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention